Gemcitabine plus nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study

被引：1
|
作者：
Zaibet, S. [1 ]
Hautefeuille, V. [2 ]
Auclin, E. [1 ]
Lievre, A. [3 ]
Tougeron, D. [4 ,5 ]
Sarabi, M. [6 ]
Gilabert, M. [7 ]
Wasselin, J.
Edeline, J. [8 ]
Artru, P. [9 ]
Bechade, D. [10 ]
Morin, C. [6 ]
Taieb, J. [11 ]
Pernot, S. [10 ]
机构：
[1] AP HP, Paris, France
[2] CHU Amiens, Amiens, France
[3] CHU Rennes, Rennes, France
[4] Univ Poitiers Hosp, Gastroenterol Dept, Poitiers, France
[5] Univ Poitiers, Poitiers, France
[6] Ctr Leon Berard, Lyon, France
[7] Inst Paoli Calmettes, Marseille, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Hop Prive Jean Mermoz, Lyon, France
[10] Inst Bergonie, Bordeaux, France
[11] Paris Descartes Univ, Georges Pompidou European Hosp, Sorbonne Paris Cite, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.462
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-6
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [31] Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine plus nab-paclitaxel (NabG).
    Schmidt, Shannon Leah
    Durkal, Vipal
    Jayavalsan, Shinoj Pattali
    Thomas, James P.
    Ritch, Paul S.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [32] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
  • [33] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [34] Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy
    Portal, Alix
    Pernot, Simon
    Siauve, Nathalie
    Landi, Bruno
    Lepere, Celine
    Colussi, Orianne
    Rougier, Philippe
    Zaanan, Aziz
    Verriere, Benjamin
    Taieb, Julien
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (02) : E23 - E26
  • [35] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in metastatic pancreatic adenocarcinoma.
    Assenat, Eric
    De La Fouchardiere, Christelle
    Mollevi, Caroline
    Samalin, Emmanuelle
    Portales, Fabienne
    Desseigne, Francoise
    Carenco, Christophe
    Dupuy, Marie
    Lopez-Martinez, Ernesto
    Fiess, Catherine
    Mazard, Thibault
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : 188 - 194
  • [38] Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.
    Assenat, Eric
    De La Fouchardiere, Christelle
    Mollevi, Caroline
    Samalin, Emmanuelle
    Portales, Fabienne
    Desseigne, Francoise
    Carenco, Christophe
    Dupuy, Marie
    Lopez-Martinez, Ernesto
    Fiess, Catherine
    Mazard, Thibault
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [40] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Tabernero, Josep
    El-Maraghi, Robert
    Ma, Wen Wee
    Reni, Michele
    Harris, Marion
    Whorf, Robert
    Liu, Helen
    Li, Jack Shiansong
    Manax, Victoria
    Romano, Alfredo
    Lu, Brian
    Goldstein, David
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 188 - 194
12345